Name: Edaravone Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3561
Price: 4350 USD
Availability: InStock

Edaravone Market Size Share Growth Opportunities and Forecast 2022

Edaravone Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Edaravone Market is segmented By Product Type (Injection, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies),&nbsp;By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The global Edaravone market size was valued US$ XX billion in 2022&nbsp;and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).&nbsp;&nbsp;
</blockquote>

Edaravone is used to treat a nerve disease named amyotrophic lateral sclerosis (ALS). It helps to slow down the worsening of this disease. This medication is given by injection into a vein.

<h2>Market Dynamics</h2>

The edaravone market growth is driven by the demand increased significantly because FDA has approved it for the treatment of ALS. Technological advancements in edaravone will boost market growth. Companies have invested in R&amp;D to develop new, more effective products, and the high ALS incidence also boosts the market growth. Moreover, increasing demand for cost-efficient products in developing regions and ongoing clinical trials of several products.

Increasing incidence amyotrophic lateral sclerosis (ALS), is expected to drive the growth in the forecast period

According to a study published in the Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S., and the prevalence rate of ALS was 4.7 cases per 100,000 people in 2012. According to the same study, the prevalence rate increased to 5.0 cases per 100,000 people, and around 15,908 people were diagnosed with ALS in 2013. According to the National Organization for Rare Disorders (NORD), Amyotrophic Lateral Sclerosis (ALS) affects approximately 30,000 people in the United States. Approximately 5,000 new cases are diagnosed each year in the United States. In 2015, a total of 16,583 persons were diagnosed with ALS. The estimated prevalence of ALS in 2015 was 5.2 per 100,000 population. Hence, the rising incidence of ALS leads to an increase in demand for Edaravone.

Side effects associated with edaravone is likely to hamper the market growth

Side effects associated with edaravone include irregular, fast or slow, or shallow breathing, skin rash, encrusted, scaly and oozing, unusual bruising, Blistering, crusting, irritation, itching, or reddening of the skin, blue lips, fingernails, or skin, chest pain or tightness, change in walking and balance, clumsiness or unsteadiness may restrict the market growth.

&nbsp;

COVID-19 Impact Analysis

The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted major companies&#39; financial status in the urea cycle disorders treatment market. The private healthcare sector is one of the sectors, which the COVID-19 pandemic has majorly impacted. The pandemic has negatively impacted the global edaravone market in various aspects such as research and development, production, and supply of medicines. The pandemic has also affected the growth of pharmaceutical businesses of various companies across the globe due to lockdowns implemented by governments of several countries.

<h2>Segment Analysis</h2>

The injection segment is expected to hold largest share in this market segment

Edaravone injection is used to treat amyotrophic lateral sclerosis. Edaravone injection is in a class of medications called antioxidants. As it is administered intravenously, the drug is delivered immediately upon completing a response requirement, and since delivery is into a vein, there is a rapid onset of drug effects. Such immediacy results in rapid acquisition and strong maintenance of behavior anticipated increasing the segment growth in the market.

The hospital pharmacies segment is expected to hold largest share in this market segment

The hospital pharmacies held the largest share in the edaravone market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

<h2>Geographical Analysis</h2>

North America region holds the largest market share of global edaravone market 

North America accounts for the largest market share due to the factors such as the increasing prevalence of neurological diseases and higher treatment awareness, rising funding by the government agencies and private organizations in the healthcare system. For instance, according to the ALS Association, approximately 5,000 people in the U.S. are diagnosed with ALS each year, averaging 15 new cases each day. It is estimated that up to 20,000 Americans have the disease at any given time. Edaravone set foot in the U.S. market in 2017 after the endorsement of the FDA for its utilization in ALS treatment.

<h2>Competitive Landscape</h2>

The global edaravone market is moderately competitive with presence of global companies.&nbsp; Some of the key players which are contributing to the growth of the market include Sun Pharmaceutical Industries Ltd, Unichem Laboratories Ltd, UCB India Ltd, Piramal Healthcare, Mitsubishi Tanabe Pharma, Simcere, Taj Pharmaceuticals Ltd, ABIOMED., Berlin Heart, BiVACOR Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.

Edaravone Market Key Companies to Watch

Sun Pharmaceutical Industries Ltd

Overview: Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients primarily in India and the United States. It is largest Pharma Company in India and 4th largest in the world.

Product Portfolio: The Company&rsquo;s portfolio comprised of include various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology.

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the edaravone market segmentation by product type, distribution channel and region highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in edaravone market by analyzing trends and co-development deals.</li>
	<li>Excel data sheet with thousands of data points of edaravone market - level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global edaravone market report would provide an access to an approx. 61 market data table, 57 figures and 200 pages.&nbsp; 

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">&nbsp;</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet by Product Type</li>
		<li>Market Snippet by Distribution Channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing incidence amyotrophic lateral sclerosis (ALS)</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Side effects associated with edaravone</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>PEST Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Product Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Attractiveness Index, By Product Type</li>
		</ol>
		</li>
		<li>&nbsp;Injection*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Oral</li>
	</ol>
	</li>
	<li>
	<h3>By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel Segment</li>
			<li>Market Attractiveness Index, By Distribution channel Segment</li>
		</ol>
		</li>
		<li>&nbsp;Hospital Pharmacies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>Key Companies to Watch</li>
		<li>Company with disruptive technology</li>
		<li>Start Up Companies</li>
	</ol>
	</li>
	<li>
	<h3>Company Profiles</h3>

	<ol>
		<li>Sun Pharmaceutical Industries Ltd*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Unichem Laboratories Ltd</li>
		<li>UCB India Ltd</li>
		<li>Piramal Healthcare</li>
		<li>Mitsubishi Tanabe Pharma</li>
		<li>Simcere</li>
		<li>Taj Pharmaceuticals Ltd</li>
		<li>ABIOMED</li>
		<li>Berlin Heart</li>
		<li>BiVACOR Inc(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence&nbsp;&nbsp;</h3>

	<ol>
		<li>&nbsp;Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 1 Global Edaravone Market Value, By Product Type, 2021,2025 &amp; 2029($ Million)

Table 2 Global Edaravone Market Value, By Distribution Channel, 2021,2025 &amp; 2029($ Million)

Table 3 Global Edaravone Market Value, By Region, 2021,2025 &amp; 2029($ Million)

Table 4 Global Edaravone Market Value, By Product Type, 2021,2025 &amp; 2029($ Million)

Table 5 Global Edaravone Market Value, By Product Type, 2018-2029($ Million)

Table 6 Global Edaravone Market Value, By Distribution Channel, 2021,2025 &amp; 2029($ Million)

Table 7 Global Edaravone Market Value, By Distribution Channel, 2018-2029($ Million)

Table 8 Global Edaravone Market Value, By Region, 2021,2025 &amp; 2029($ Million)

Table 9 Global Edaravone Market Value, By Region, 2018-2029($ Million)

Table 10 North America Edaravone Market Value, By Product Type, 2018-2029($ Million)

Table 11&nbsp; North America Edaravone Market Value, By Distribution Channel, 2018-2029($ Million)

Table 12 North America Edaravone Market Value, By Country, 2018-2029($ Million)

Table 13 South America Edaravone Market Value, By Product Type, 2018-2029($ Million)

Table 14 South America Edaravone Market Value, By Distribution Channel, 2018-2029($ Million)

Table 15 South America Edaravone Market Value, By Country, 2018-2029($ Million)

Table 16 Europe Edaravone Market Value, By Product Type, 2018-2029($ Million)

Table 17&nbsp; Europe Edaravone Market Value, By Distribution Channel, 2018-2029($ Million)

Table 18 Europe Edaravone Market Value, By Country, 2018-2029($ Million)

Table 19 Asia-Pacific Edaravone Market Value, By Product Type, 2018-2029($ Million)

Table 20 Asia-Pacific Edaravone Market Value, By Distribution Channel, 2018-2029($ Million)

Table 21 Asia-Pacific Edaravone Market Value, By Country, 2018-2029($ Million)

Table 22 Middle East &amp; Africa Edaravone Market Value, By Product Type, 2018-2029($ Million)

Table 23 Middle East &amp; Africa Edaravone Market Value, By Distribution Channel, 2018-2029($ Million)

Table 24 Sun Pharmaceutical Industries Ltd: Overview

Table 25 Sun Pharmaceutical Industries Ltd: Product Portfolio

Table 26 Sun Pharmaceutical Industries Ltd: Key Developments

Table 27 Unichem Laboratories Ltd: Overview

Table 28 Unichem Laboratories Ltd: Product Portfolio

Table 29 Unichem Laboratories Ltd: Key Developments

Table 30 UCB India Ltd: Overview

Table 31 UCB India Ltd: Product Portfolio

Table 32 UCB India Ltd: Key Developments

Table 33 Piramal Healthcare: Overview

Table 34 Piramal Healthcare: Product Portfolio

Table 35 Piramal Healthcare: Key Developments

Table 36 Mitsubishi Tanabe Pharma: Overview

Table 37 Mitsubishi Tanabe Pharma: Product Portfolio

Table 38 Mitsubishi Tanabe Pharma: Key Developments

Table 39 Simcere: Overview

Table 40 Simcere: Product Portfolio

Table 41 Simcere: Key Developments

Table 42 Taj Pharmaceuticals Ltd: Overview

Table 43 Taj Pharmaceuticals Ltd: Product Portfolio

Table 44 Taj Pharmaceuticals Ltd: Key Developments

Table 45 ABIOMED: Overview

Table 46 ABIOMED: Product Portfolio

Table 47 ABIOMED: Key Developments

Table 48 Berlin Heart: Overview

Table 49 Berlin Heart: Product Portfolio

Table 50 Berlin Heart: Key Developments

Table 51 BiVACOR Inc: Overview

Table 52 BiVACOR Inc: Product Portfolio

Table 53 BiVACOR Inc: Key Developments

List of Figures

Figure 1&nbsp; Global Edaravone Market Share, By Product Type, 2021 &amp; 2029(%)

Figure 2 Global Edaravone Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 3 Global Edaravone Market Share, By Region, 2021 &amp; 2029(%)

Figure 4 Global Edaravone Market Value, 2018-2029($ Million)

Figure 5 Global Edaravone Market Y-o-Y Growth, By Product Type, 2021 &amp; 2029(%)

Figure 6 Oral: Global Edaravone Market Value, 2018-2029($ Million)

Figure 7&nbsp; Injection: Global Edaravone Market Value, 2018-2029($ Million)

Figure 8 Global Edaravone Market Y-o-Y Growth, By Distribution Channel, 2021 &amp; 2029(%)

Figure 9 Hospital Pharmacies: Global Edaravone Market Value, 2018-2029($ Million)

Figure 10 Retail Pharmacies: Global Edaravone Market Value, 2018-2029($ Million)

Figure 11&nbsp; Online Pharmacies: Global Edaravone Market Value, 2018-2029($ Million)

Figure 12 Global Edaravone Market Y-o-Y Growth, By Region, 2021 &amp; 2029(%)

Figure 13 North America Edaravone Market Value, 2018-2029($ Million)

Figure 14 North America Edaravone Market Share, By Product Type, 2021 &amp; 2029(%)

Figure 15 North America Edaravone Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 16 North America Edaravone Market Share, By Country, 2021 &amp; 2029(%)

Figure 17&nbsp; South America Edaravone Market Value, 2018-2029($ Million)

Figure 18 South America Edaravone Market Share, By Product Type, 2021 &amp; 2029(%)

Figure 19 South America Edaravone Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 20 South America Edaravone Market Share, By Country, 2021 &amp; 2029(%)

Figure 21 Europe Edaravone Market Value, 2018-2029($ Million)

Figure 22 Europe Edaravone Market Share, By Product Type, 2021 &amp; 2029(%)

Figure 23 Europe Edaravone Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 24 Europe Edaravone Market Share, By Country, 2021 &amp; 2029(%)

Figure 25 Asia-Pacific Edaravone Market Value, 2018-2029($ Million)

Figure 26 Asia-Pacific Edaravone Market Share, By Product Type, 2021 &amp; 2029(%)

Figure 27 Asia-Pacific Edaravone Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 28 Asia-Pacific Edaravone Market Share, By Country, 2021 &amp; 2029(%)

Figure 29 Middle East &amp; Africa Edaravone Market Value, 2018-2029($ Million)

Figure 30 Middle East &amp; Africa Edaravone Market Share, By Product Type, 2021 &amp; 2029(%)

Figure 31 Middle East &amp; Africa Edaravone Market Share, By Distribution Channel, 2021 &amp; 2029(%)

Figure 32 Sun Pharmaceutical Industries Ltd: Financials

Figure 33 Unichem Laboratories Ltd: Financials

Figure 34 UCB India Ltd: Financials

Figure 35 Piramal Healthcare: Financials

Figure 36 Mitsubishi Tanabe Pharma: Financials

Figure 37 Simcere: Financials

Figure 38 Taj Pharmaceuticals Ltd: Financials

Figure 39 ABIOMED: Financials

Figure 40 Berlin Heart: Financials

Figure 41 BiVACOR Inc: Financials